Capecitabine

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Metastatic Colorectal Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

Also approved (3)
US
  • Perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy
  • Adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease, as a component of a combination regimenOutside this platform's coverage
Product first approved 1998FDA label
EU
  • Xeloda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer. Xeloda is indicated for the treatment of metastatic colorectal cancer. Xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Xeloda is also indicated as monotherapy for the treatment...
Product first approved 2001EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (269)
Colorectal Cancer
NCT07340567 · UNICANCER
2026-07-20 – 2035-11-01 · Colorectal Cancer
What this study did
NCT05797077 · Sixth Affiliated Hospital, Sun Yat-sen University
2023-02-20 – 2031-02-20 · Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Cancer, Therapy-Related
What this study did
NCT05236972 · Sun Yat-sen University
2022-01-01 – 2028-12-31 · Colorectal Carcinoma
What this study did
NCT05699746 · Zhejiang University
2023-03 – 2026-12 · Colorectal Cancer
What this study did
NCT05327751 · Tanta University
2022-04-01 – 2025-04-01 · Hand and Foot Syndrome, Erythrodysesthesia Syndrome, HFS, Colorectal Cancer
What this study did
NCT03038217 · Peking Union Medical College Hospital
2017-02 – 2021-12 · Rectal Cancer, Adenocarcinoma, Neoadjuvant Chemoradiation
What this study did
NCT01996306 · Epidemiological and Clinical Research Information Network
2013-12-02 – 2018-06-30 · Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms
What this study did
NCT02316535 · West China Hospital
2014-11 – 2018-05 · Colorectal Neoplasms
What this study did
NCT00749450 · Cancer Research UK, Glasgow
2008-03 – 2017-11 · Colorectal Cancer
What this study did
NCT01249638 · Ludwig-Maximilians - University of Munich
2010-12 – 2016-12 · Colorectal Cancer Metastatic
What this study did
NCT00058474 · NSABP Foundation Inc
2004-07 – 2016-05 · Colorectal Cancer
What this study did
NCT00630045 · Peking University People's Hospital
2008-01 – 2015-06 · Colorectal Cancer, Resectable Liver Metastasis
What this study did
NCT00482222 · University of Southampton
2007-02 – 2014-12 · Colorectal Cancer, Metastatic Cancer
What this study did
NCT00394992 · Dutch Colorectal Cancer Group
2006-12 – 2013-08 · Colorectal Cancer, Liver Metastases
What this study did
NCT00112918 · Hoffmann-La Roche
2004-12 – 2012-06 · Colorectal Cancer
What this study did
NCT01097018 · AEterna Zentaris
2010-04 – 2012-04 · Colorectal Cancer
What this study did
NCT01167725 · Alliance for Clinical Trials in Oncology
2010-08 – 2012-01 · Colorectal Cancer
What this study did
NCT00062426 · Prologue Research International
2003-05 – 2011-02 · Colorectal Cancer
What this study did
NCT00469443 · Hellenic Oncology Research Group
2006-12 – 2010-02 · Colorectal Cancer
What this study did
NCT00156975 · Arbeitsgruppe Lebermetastasen und Tumoren
started 2004-11 · Colorectal Neoplasms, Liver Metastases
What this study did
NCT00208546 · Dutch Colorectal Cancer Group
2005-06 – 2009-12 · Colorectal Cancer
What this study did
NCT00101686 · Pfizer
2003-02 – 2008-10 · Colorectal Neoplasms
What this study did
NCT00427713 · Cancer Research UK
2004-11 – 2008-03 · Colorectal Cancer
What this study did
NCT00070122 · National Cancer Institute (NCI)
2004-04 – 2007-01 · Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
What this study did
NCT00312000 · Dutch Colorectal Cancer Group
2003-01 – 2006-12 · Advanced Colorectal Cancer
What this study did
NCT00189683 · Association Européenne de Recherche en Oncologie
— · Colorectal Cancer
What this study did
NCT00212589 · Odense University Hospital
2002-12 – 2004-04 · Colorectal Cancer
What this study did
Gastric Cancer
NCT07431281 · AstraZeneca
2026-02-03 – 2031-10-27 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
What this study did
NCT06764875 · AstraZeneca
2025-03-01 – 2030-12-09 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06313567 · Fudan University
2024-03-10 – 2029-03-10 · Gastric Cancer
What this study did
NCT07677293 · Peking University
2026-06-26 – 2028-12-31 · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06532006 · Shanghai Henlius Biotech
2024-11-22 – 2028-09-01 · Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
What this study did
NCT01935778 · Asan Medical Center
2013-10-02 – 2028-06-30 · Gastric Cancer, Adjuvant Chemotherapy, XO
What this study did
NCT04248452 · ECOG-ACRIN Cancer Research Group
2020-05-26 – 2028-03-31 · Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
What this study did
NCT04787354 · Hallym University Medical Center
2021-11-01 – 2027-12-31 · Gastric Cancer
What this study did
NCT04997837 · Fudan University
2021-07-21 – 2027-10-21 · Gastric Cancer
What this study did
NCT03399110 · Fudan University
2018-01-14 – 2026-08-15 · Gastric Cancer
What this study did
NCT01917552 · Asan Medical Center
2013-08-19 – 2026-08-01 · Gastric Cancer
What this study did
NCT03817268 · The First Affiliated Hospital of Anhui Medical University
2019-01-16 – 2026-01-30 · Gastric Cancer
What this study did
NCT00407186 · Dutch Colorectal Cancer Group
2007-01-11 – 2025-12 · Gastric Cancer
What this study did
NCT03221426 · Merck Sharp & Dohme LLC
2017-10-09 – 2025-04-23 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT04882241 · Merck Sharp & Dohme LLC
2020-07-29 – 2025-04-23 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT02872116 · Bristol-Myers Squibb
2016-10-12 – 2024-06-06 · Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
What this study did
NCT04351867 · LiNing
2020-09 – 2024-06 · Stomach Neoplasms
What this study did
NCT03889626 · Fudan University
2019-03-22 – 2024-03-22 · Stomach Neoplasms, Gastrointestinal Neoplasms, Stomach Diseases, Digestive System Neoplasms, Capecitabine, Apatinib, Neoplasms, Molecular Mechanisms of Pharmacological Action
What this study did
Phase 2/3 (54)
Colorectal Cancer
NCT03577392 · Sichuan Provincial People's Hospital
2018-07-01 – 2021-08-01 · Quality of Life
What this study did
NCT01196260 · State Key Laboratory of Cancer Biology
2004-01 – 2020-12 · Colorectal Cancer
What this study did
NCT00647530 · University of Birmingham
2008-05-15 – 2019-12-31 · Colorectal Cancer
What this study did
NCT02893540 · Ruijin Hospital
2016-09 – 2019-08 · Colorectal Cancer
What this study did
NCT01097265 · Jeroen Bosch Ziekenhuis
2010-07 – 2015-01 · Colorectal Cancer
What this study did
Gastric Cancer
NCT07332533 · Shanghai JMT-Bio Inc.
2025-12-30 – 2032-12-31 · HER2-positive Gastric Cancer
What this study did
NCT05980481 · RemeGen Co., Ltd.
2023-08-04 – 2026-10-10 · Gastric Cancer
What this study did
NCT03607656 · Shanghai University of Traditional Chinese Medicine
2018-06-08 – 2023-11-30 · Gastric Cancer Stage IIIB, Gastric Cancer Stage IIIC
What this study did
NCT02746796 · Ono Pharmaceutical Co., Ltd.
2016-03 – 2022-11-17 · Gastric Cancer
What this study did
NCT01516944 · Hebei Medical University
2012-02 – 2018-12 · Gastric Cancer
What this study did
NCT00450203 · Professor David Cunningham
2007-10 – 2017-12 · Oesophagogastric Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT03423849 · Zhiyong Yu
2018-02-08 – 2020-02-08 · Breast Cancer, Chemotherapy Effect, Disease-free Survival
What this study did
NCT00418028 · Hospital San Carlos, Madrid
2005-09 – 2015-01 · Metastatic Breast Cancer
What this study did
NCT00684216 · The Netherlands Cancer Institute
2008-04 – 2013-05 · Breast Cancer
What this study did
NCT00201435 · Norwegian Breast Cancer Group
2005-03 – 2008-05 · Breast Neoplasm
What this study did
NCT00049660 · European Organisation for Research and Treatment of Cancer - EORTC
2002-09 – 2004-12 · Breast Cancer
What this study did
Metastatic Colorectal Cancer
NCT07462143 · RemeGen Co., Ltd.
2026-05-12 – 2030-12-31 · Colorectal (Colon or Rectal) Cancer
What this study did
NCT03158610 · Ruijin Hospital
2018-01-29 – 2021-04-28 · Colorectal Cancer
What this study did
NCT00212615 · Odense University Hospital
2004-02 – 2008-10 · C04.588.274.476.411.307
What this study did
NCT00294359 · Australasian Gastro-Intestinal Trials Group
2005-06 – 2007-07 · Metastatic Colorectal Cancer
What this study did
Pancreatic Cancer
NCT03959150 · Ruijin Hospital
2020-01-05 – 2023-06-30 · Pancreatic Cancer
What this study did
NCT03512756 · Tyme, Inc
2018-03-27 – 2021-12-28 · Pancreatic Cancer
What this study did
NCT01065870 · Columbia University
2009-12 – 2014-12 · Pancreatic Cancer Stage II, Pancreatic Cancer Stage III
What this study did
NCT00960284 · IRCCS San Raffaele
2003-06 – 2009-06 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT05610163 · Alliance for Clinical Trials in Oncology
2022-12-08 – 2037-07-01 · Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
What this study did
NCT04803539 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-04-01 – 2033-09-01 · Breast Cancer
What this study did
NCT07490262 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
2026-03-27 – 2030-12-31 · Hepatocellular Carcinoma (HCC)
What this study did
NCT06841679 · Beijing Biostar Pharmaceuticals Co., Ltd.
2025-08-28 – 2030-09-01 · Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07309419 · Shanghai Zhongshan Hospital
2025-12-22 – 2030-06-30 · Hepatocellular Carcinoma
What this study did
NCT07392866 · Nanjing Sanhome Pharmaceutical, Co., Ltd.
2026-03-01 – 2030-03-01 · Hepatocellular Carcinoma (HCC)
What this study did
NCT05288777 · University of Virginia
2022-07-11 – 2029-12 · Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
What this study did
NCT05902533 · University of Cincinnati
2023-08-14 – 2029-08-14 · Anal Cancer
What this study did
NCT07366840 · Fudan University
2026-01-16 – 2029-01-16 · HER2-positive Breast Cancer, Metastatic Breast Cancer
What this study did
NCT02945566 · University of Birmingham
2017-06-14 – 2028-08 · Adenocarcinoma of the Rectum
What this study did
NCT06719479 · SUNHO(China)BioPharmaceutical CO., Ltd.
2025-01-01 – 2028-01-01 · NPC, HNSCC, Recurrence, Metastasis
What this study did
NCT05976568 · Qilu Pharmaceutical Co., Ltd.
2023-09-01 – 2027-09-01 · Hepatocellular Carcinoma
What this study did
NCT06268327 · Assiut University
2024-04-30 – 2026-10-30 · Breast Cancer
What this study did
NCT04068103 · NRG Oncology
2019-12-16 – 2026-06-21 · Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
What this study did
NCT05065957 · InnoPharmax Inc.
2022-03-29 – 2025-07-31 · Biliary Tract Cancer
What this study did
NCT05348278 · Mahidol University
2021-12-20 – 2023-08 · Hand-Foot Syndrome
What this study did
NCT02741856 · Lisette Nixon
2016-11-04 – 2023-04 · Oesophageal Cancer
What this study did
NCT01662128 · Tianjin Medical University
2012-06 – 2022-06 · Breast Cancer
What this study did
NCT01962246 · Hebei Medical University
2012-02 – 2021-08 · Gastroesophageal Junction Adenocarcinoma
What this study did
NCT00397761 · Medstar Health Research Institute
started 2006-07 · Breast Cancer
What this study did
NCT03507465 · Guangdong Provincial People's Hospital
2017-11-29 – 2020-11-29 · Breast Cancer
What this study did
NCT02311439 · Assiut University
2014-10 – 2017-04 · Cancer of Pancreas
What this study did
NCT03428529 · Instituto Nacional de Cancer, Brazil
2011-01-12 – 2016-12-13 · Rectal Neoplasm Malignant
What this study did
NCT01064999 · Fudan University
2010-03 – 2014-12 · Rectal Cancer
What this study did
Phase 2 (904)
Colorectal Cancer
NCT07570914 · Tianjin Medical University Cancer Institute and Hospital
2026-05-30 – 2032-05-30 · Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer, Liver Metastasis
What this study did
NCT07134101 · The First Affiliated Hospital with Nanjing Medical University
2025-09-01 – 2030-08-31 · Colorectal Cancer (Diagnosis)
What this study did
NCT07281768 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2026-07-14 – 2030-07 · Colorectal Cancer
What this study did
NCT07503639 · Fudan University
2026-04 – 2030-04 · Locally Advanced Colorectal Cancer
What this study did
NCT07215936 · Sohag University
2025-09-25 – 2028-09 · Colorectal Cancer
What this study did
NCT06881537 · Shanghai Changzheng Hospital
2024-06-01 – 2028-06-30 · Locally Recurrent Colorectal Cancer
What this study did
NCT06888843 · Nizhny Novgorod Regional Clinical Oncology Center
2025-02-01 – 2028-02-01 · Colorectal Cancer
What this study did
NCT07562659 · Fudan University
2024-11-01 – 2027-12-31 · ctDNA, Colorectal Cancer (CRC), Adjuvant Chemotherapy
What this study did
NCT07691632 · Tianjin Medical University Cancer Institute and Hospital
2026-06-30 – 2027-12-31 · Locally Advanced Colorectal Cancer, Colorectal Adenocarcinoma
What this study did
NCT06540326 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-11-12 – 2027-10-31 · Colorectal Cancer Metastatic
What this study did
NCT05489211 · AstraZeneca
2022-09-06 – 2027-10-01 · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
What this study did
NCT06788171 · Fujian Cancer Hospital
2026-05-09 – 2027-09-01 · Colorectal Cancer Liver Metastasis
What this study did
NCT06405139 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-05-01 – 2027-04-30 · Colorectal Cancer
What this study did
NCT06885385 · Shanghai Junshi Bioscience Co., Ltd.
2025-04-23 – 2027-02-13 · Advanced Colorectal Cancer
What this study did
NCT04304209 · Sun Yat-sen University
2019-10-28 – 2026-10-18 · Colorectal Cancer Stage II, Colorectal Cancer Stage III
What this study did
NCT05720559 · Liaoning Cancer Hospital & Institute
2023-03-01 – 2026-09-01 · Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer
What this study did
NCT06490913 · Fujian Cancer Hospital
2024-11-01 – 2025-12-31 · Liver Metastases of Colorectal Cancer
What this study did
NCT06332079 · Gruppo Oncologico del Nord-Ovest
2024-03-13 – 2025-12-16 · Colorectal Cancer Metastatic
What this study did
NCT06206096 · Chinese PLA General Hospital
2021-05-26 – 2025-12 · Colorectal Cancer, RAS Mutation, Colorectal Neoplasms, Microsatellite Stable Colorectal Carcinoma
What this study did
NCT05588297 · Shanghai Changzheng Hospital
2022-10 – 2025-10 · Colorectal Cancer Liver Metastases
What this study did
NCT03929666 · Jazz Pharmaceuticals
2019-08-22 – 2025-08-30 · HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
What this study did
NCT03984578 · National Cancer Centre, Singapore
2019-06-12 – 2025-02-28 · Colorectal Cancer
What this study did
NCT03280407 · Zealand University Hospital
2017-03-01 – 2024-12-31 · Colorectal Neoplasm, Colorectal Cancer, Rectal Neoplasms, Chemotherapy Effect, Intestinal Disease, Intestinal Neoplasms, Rectal Cancer
What this study did
NCT04301557 · Sun Yat-sen University
2020-07-31 – 2024-12-30 · DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer
What this study did
NCT04911517 · Beijing Friendship Hospital
2021-06-01 – 2024-12 · Colorectal Neoplasms
What this study did
NCT05648006 · Binhui Biopharmaceutical Co., Ltd.
2023-10-17 – 2024-04-15 · Advanced Colorectal Carcinoma
What this study did
NCT03396926 · University of California, San Francisco
2018-04-18 – 2024-01-30 · Microsatellite Stable, Mismatch Repair Protein Proficient, Stage III Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
NCT04324476 · Jiangsu Cancer Institute & Hospital
2019-09-01 – 2023-06 · Advanced Colorectal Cancer
What this study did
NCT05018182 · West China Hospital
2021-08-02 – 2022-08-02 · High-risk Locally Advanced Colorectal Cancer, Neoadjuvant Chemotherapy, FOLFOXIRI Regimen
What this study did
NCT04080843 · Zhejiang University
2019-11-15 – 2022-07-01 · Colorectal Cancer, RAS and BRAF Wild-type, Colorectal Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases
What this study did
NCT01776307 · Sumitomo Pharma America, Inc.
2012-03 – 2020-04 · Colorectal Cancer
What this study did
NCT02830139 · Wuhan University
2016-07 – 2020-03-15 · Malignant Neoplasm of Colorectum
What this study did
NCT02280694 · HaEmek Medical Center, Israel
2015-01 – 2019-12 · Colorectal Cancer
What this study did
NCT01880658 · Sun Yat-sen University
2013-06 – 2019-05 · Colorectal Neoplasms
What this study did
NCT00686166 · SWOG Cancer Research Network
2009-02 – 2018-03 · Colorectal Cancer
What this study did
NCT02086656 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2013-06 – 2017-03-30 · Colorectal Cancer Liver Metastases
What this study did
NCT00081289 · Radiation Therapy Oncology Group
2004-03 – 2016-12 · Colorectal Cancer
What this study did
NCT00613080 · Radiation Therapy Oncology Group
2008-04 – 2016-12 · Colorectal Cancer
What this study did
NCT01677884 · Gustave Roussy, Cancer Campus, Grand Paris
2012-11 – 2016-02 · Colorectal Neoplasms
What this study did
NCT01290926 · Jules Bordet Institute
2011-02 – 2016-01 · Colorectal Cancer
What this study did
NCT02415829 · Fudan University
2014-11 – 2016-01 · Colorectal Cancer
What this study did
NCT00997685 · Guangdong Provincial People's Hospital
2009-11 – 2015-10 · Potentially Resectable Liver Metastasis From CRC, Colorectal Cancer
What this study did
NCT01722162 · Washington University School of Medicine
2013-04 – 2015-10 · Colorectal Neoplasms
What this study did
NCT00114231 · Alliance for Clinical Trials in Oncology
2006-05 – 2014-12 · Colorectal Cancer
What this study did
NCT01668680 · HaEmek Medical Center, Israel
2012-09 – 2014-12 · Colorectal Cancer Metastatic
What this study did
NCT00416494 · Herbert Hurwitz, MD
2003-09 – 2014-08 · Colorectal Cancer
What this study did
NCT02027363 · Sun Yat-sen University
2010-01 – 2014-06 · Colorectal Neoplasms, Neoplasms Metastasis
What this study did
NCT00659022 · Radboud University Medical Center
2008-07 – 2014-04 · Colorectal Neoplasms, Liver Neoplasms
What this study did
NCT00814619 · Swiss Cancer Institute
2008-11 – 2014-01 · Colorectal Cancer
What this study did
NCT00321100 · Fox Chase Cancer Center
2006-04-12 – 2013-12-18 · Colorectal Neoplasms
What this study did
Phase 1/2 (182)
Colorectal Cancer
NCT07805551 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2026-08-18 – 2032-08 · CRC, Colorectal Cancer
What this study did
NCT07283367 · Hansoh BioMedical R&D Company
2025-12-22 – 2029-12-31 · CRC
What this study did
NCT07365592 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-04-09 – 2029-12-31 · Colorectal Cancer
What this study did
NCT07737600 · Lepu Biopharma Co., Ltd.
2026-08 – 2029-12 · Advanced Colorectal Cancer
What this study did
NCT07683949 · Seoul National University Bundang Hospital
2026-06-15 – 2029-10-31 · Advanced Colorectal Cancer (Part 1)
What this study did
NCT07551778 · BOE Technology Group Co., Ltd.
2026-08 – 2029-04 · NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular Carcinoma (HCC), GC/GEJC
What this study did
NCT06324357 · Boehringer Ingelheim
2024-06-28 – 2029-01-08 · Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal Cancer
What this study did
NCT05700656 · The Netherlands Cancer Institute
2023-07-28 – 2026-12 · Colorectal Cancer Metastatic, Peritoneal Carcinomatosis
What this study did
NCT04940546 · Sun Yat-sen University
2021-06-16 – 2025-10-30 · Colorectal Cancer Metastatic
What this study did
NCT04751955 · Korean Cancer Study Group
2022-01-01 – 2024-08-31 · Colorectal Cancer Metastatic
What this study did
NCT01898104 · National Cancer Institute, Naples
2012-05 – 2024-04 · Colorectal Cancer
What this study did
NCT02861300 · David Bajor, MD
2016-09-12 – 2023-01-10 · Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
What this study did
NCT04227041 · Qingdao Zhixin Health Technology Co., Ltd.
2020-01-10 – 2023-01-10 · HER-2 Positive Colorectal Cancer
What this study did
NCT04701281 · AllVascular
2022-03-02 – 2022-10-19 · Liver Metastasis Colon Cancer
What this study did
NCT05091528 · Silverback Therapeutics
2022-02-08 – 2022-07-07 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
What this study did
NCT03169777 · ImmunityBio, Inc.
2018-08 – 2021-12-28 · Colorectal Cancer
What this study did
NCT04202978 · Zhongshan Hospital Xiamen University
2020-03-01 – 2021-11-01 · Hepatic Metastasis of Colorectal Cancer
What this study did
NCT03564912 · Zhejiang University
2018-08-12 – 2021-08-24 · Colorectal Cancer
What this study did
NCT03470350 · The Netherlands Cancer Institute
2018-08-24 – 2020-06-01 · Colorectal Cancer Metastatic
What this study did
NCT04031872 · The Netherlands Cancer Institute
2020-01-01 – 2020-01-01 · Colorectal Cancer Metastatic
What this study did
NCT03563157 · ImmunityBio, Inc.
2018-09-28 – 2019-08-21 · Colorectal Cancer Metastatic, mCRC
What this study did
NCT00869570 · Swiss Cancer Institute
2009-03 – 2016-09 · Colorectal Cancer
What this study did
NCT00784446 · University of Cologne
2008-04 – 2012-12 · Stage IV Colorectal Cancer
What this study did
NCT00345761 · Chugai Pharmaceutical
2006-02 – 2010-07 · Colorectal Cancer
What this study did
NCT00086931 · Roswell Park Cancer Institute
2003-09 – 2010-05 · Colorectal Cancer
What this study did
NCT01016639 · Lund University Hospital
2003-06 – 2009-07 · Stomach Cancer, Gall Bladder Cancer, Bile Ductus Cancer, Pancreas Cancer, Colorectal Cancer
What this study did
NCT00242788 · AstraZeneca
2004-02 – 2005-11 · Colorectal Cancer
What this study did
NCT00081536 · Aronex Pharmaceuticals
— · Colorectal Neoplasms
What this study did
Gastric Cancer
NCT07040059 · Aurigene Discovery Technologies Limited
2025-03-22 – 2025-12-29 · HER 2 Positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT04963088 · The First Affiliated Hospital with Nanjing Medical University
2021-03-06 – 2024-03-20 · Gastric Cancer
What this study did
NCT02901301 · Yonsei University
2017-02-06 – 2021-10 · Gastric Cancer
What this study did
NCT01045538 · Asan Medical Center
2010-02 – 2016-04 · Gastric Cancer, Histone Deacetylase Inhibitor
What this study did
NCT01348009 · Genta Incorporated
2011-05 – 2014-01 · Gastric Carcinoma
What this study did
NCT01099527 · Samsung Medical Center
2009-10 – 2013-12 · Metastatic Gastric Cancer
What this study did
NCT01355302 · Eisai Inc.
2011-11 – 2013-07 · Advanced or Metastatic Solid Tumors, Previously Untreated Gastric Cancer
What this study did
NCT00719550 · Amgen
2009-02 – 2013-06 · Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer
What this study did
NCT00845884 · Rabin Medical Center
2009-02 – 2012-12 · Advanced Gastric Cancer
What this study did
NCT01611506 · Dr Anna Dorothea Wagner
2012-02 – 2012-12 · Gastric Cancer
What this study did
NCT00565370 · Asan Medical Center
2007-11 – 2009-12 · Advanced Gastric Cancer
What this study did
NCT00021047 · National Institutes of Health Clinical Center (CC)
2001-07 – 2004-06 · Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06374459 · Washington University School of Medicine
2025-01-30 – 2032-05-31 · Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
What this study did
NCT06942234 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2025-06-01 – 2027-12-31 · Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
What this study did
NCT06202261 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2023-04-13 – 2027-10 · Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies
What this study did
NCT02734290 · Providence Health & Services
2016-02-23 – 2026-12 · Triple Negative Breast Cancer
What this study did
NCT05845138 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2023-07-25 – 2025-12-31 · Breast Cancer
What this study did
NCT05535413 · Hunan Cancer Hospital
2023-01-01 – 2025-07 · Metastatic HER2 Negative Breast Carcinoma, Brain Metastases, Capecitabine, UDT1
What this study did
Phase 1 (236)
Colorectal Cancer
NCT06963502 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2025-05-30 – 2030-04-30 · Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer
What this study did
NCT06328738 · Enliven Therapeutics
2024-05-30 – 2028-07 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
What this study did
NCT06839105 · Shanghai Junshi Bioscience Co., Ltd.
2025-02-21 – 2028-04-30 · Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
What this study did
NCT06547385 · Ono Pharmaceutical Co., Ltd.
2021-01-13 – 2027-10-31 · Colorectal Cancer
What this study did
NCT01061515 · Washington University School of Medicine
2011-05-10 – 2027-09-27 · Carcinoma
What this study did
NCT05803382 · National Cancer Institute (NCI)
2023-11-08 – 2027-06-30 · Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Malignant Solid Neoplasm
What this study did
NCT05464030 · EMD Serono Research & Development Institute, Inc.
2022-08-04 – 2026-10-23 · Colorectal Cancer
What this study did
NCT03153280 · Cancer Trials Ireland
2022-01-13 – 2023-09-07 · Colorectal Neoplasms, Stomach Neoplasm, Esophageal Neoplasms
What this study did
NCT00019773 · National Cancer Institute (NCI)
started 1999-07 · Carcinoma of the Appendix, Colorectal Cancer, Small Intestine Cancer
What this study did
NCT01306630 · AVEO Pharmaceuticals, Inc.
2010-11 – 2014-01 · Advanced Solid Tumors, Locally Advanced or Metastatic Breast or Colorectal Cancer
What this study did
NCT02720926 · National Cancer Centre, Singapore
2011-09 – 2012-01 · Colorectal Cancer, Gastric Cancer
What this study did
NCT00296062 · Case Comprehensive Cancer Center
2006-03 – 2011-05 · Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00107250 · NCIC Clinical Trials Group
2005-01-21 – 2011-01-18 · Colorectal Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00183833 · University of Southern California
2002-12 – 2010-08 · Colon Cancer, Colorectal Cancer
What this study did
NCT00536809 · GlaxoSmithKline
2007-09-26 – 2008-10-31 · Neoplasms, Colorectal
What this study did
NCT00084591 · Fox Chase Cancer Center
2003-12 – 2007-02 · Colorectal Cancer
What this study did
NCT00003704 · Alliance for Clinical Trials in Oncology
1999-04 – 2003-07 · Cancer
What this study did
Gastric Cancer
NCT04523818 · M.D. Anderson Cancer Center
2020-08-11 – 2028-12-31 · Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8
What this study did
NCT05296005 · Ohio State University Comprehensive Cancer Center
2025-12-31 – 2025-12-31 · Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
What this study did
NCT03515941 · Tannaz Armaghany
2018-06-22 – 2020-06-18 · Gastrointestinal Cancer
What this study did
NCT01049620 · Asan Medical Center
2010-02 – 2013-09 · Advanced Gastric Cancer
What this study did
NCT00842244 · Pfizer
2009-04 – 2012-10 · Stomach Neoplasms, Advanced Gastric Cancer
What this study did
NCT00601510 · Technical University of Munich
2007-11 – 2012-01 · Gastric Cancer
What this study did
NCT00555620 · Pfizer
2008-05 – 2011-12 · Stomach Neoplasms
What this study did
NCT00960349 · AstraZeneca
2009-08 – 2011-03 · Gastric Cancer
What this study did
NCT00486356 · University of Nebraska
2004-10-01 – 2010-01-01 · Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00113581 · Merck KGaA, Darmstadt, Germany
2002-10 – 2007-01 · Esophageal Cancer, Gastric Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT04556773 · AstraZeneca
2020-12-17 – 2027-06-01 · Metastatic Breast Cancer
What this study did
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT05553522 · Baptist Health South Florida
2024-01-29 – 2025-12-17 · Brain Metastases, HER2-positive Breast Cancer
What this study did
NCT05064085 · H. Lee Moffitt Cancer Center and Research Institute
2021-10-12 – 2025-03-13 · Hormone Receptor-positive Breast Cancer
What this study did
NCT03775525 · Genzada Pharmaceuticals USA, Inc.
2019-03-01 – 2023-12 · Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
What this study did
NCT02009449 · Eli Lilly and Company
2013-11-15 – 2023-07-22 · Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
What this study did
NCT02754011 · UNICANCER
2017-02-02 – 2022-12-23 · Breast Cancer
What this study did
NCT02915172 · M.D. Anderson Cancer Center
2016-12 – 2022-12 · Advanced Cancer, Malignant Neoplasm of Breast, Malignant Neoplasms of Bone and Articular Cartilage, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Mesothelial and Soft Tissue, Malignant Neoplasms of Respiratory and Intrathoracic Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands, Malignant Neoplasms of Urinary Tract
What this study did
NCT03473639 · University of Virginia
2019-01-29 – 2022-11-01 · Metastatic Breast Cancer, Breast Cancer
What this study did
NCT05052437 · Beijing Biostar Pharmaceuticals Co., Ltd.
2020-10-15 – 2021-02-19 · Advanced and Metastatic Breast Cancer
What this study did
NCT02650752 · Memorial Sloan Kettering Cancer Center
2016-01-06 – 2021-01-22 · Metastatic Breast Cancer, Central Nervous System (CNS) Metastases
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT04420871 · The Affiliated Hospital of Qingdao University
2018-12-10 – 2019-01-26 · Patient Participation
What this study did
NCT01300962 · UNC Lineberger Comprehensive Cancer Center
2011-08 – 2018-12-31 · Metastatic Breast Cancer
What this study did
NCT03435666 · Qilu Pharmaceutical Co., Ltd.
2018-05 – 2018-11 · Colon Cancer, Breast Cancer
What this study did
NCT00049244 · R-Pharm
started 2002-09 · Breast Cancer
What this study did
NCT01843725 · Jules Bordet Institute
2013-09 – 2016-10 · Metastatic Colorectal Cancers, Metastatic Gastric Cancers, Metastatic Oesophageal Cancers, Metastatic Pancreatic Cancers, Metastatic Biliary Cancers, Metastatic Breast Cancers
What this study did
NCT02210364 · PharmaMar
2013-04 – 2016-10 · Metastatic Breast Cancer, Pancreatic Cancer, Metastatic Colorectal Cancer
What this study did
NCT01640665 · Yale University
2012-07 – 2014-08 · Metastatic Breast Cancer, Gastrointestinal Tumors
What this study did
NCT01238029 · Sponsor GmbH
2010-10 – 2014-07 · Metastatic Breast Cancer, HER2 Positive, First or Second Line Therapy, Failure or Contraindication of Trastuzumab Therapy
What this study did
Phase 4 (29)
Colorectal Cancer
NCT01641458 · Cantonal Hospital of St. Gallen
2012-10 – 2015-11 · Colorectal Cancer
What this study did
NCT00502671 · Hoffmann-La Roche
2007-07 – 2012-03 · Colorectal Cancer
What this study did
NCT00577031 · Hoffmann-La Roche
2008-02 – 2011-08 · Colorectal Cancer
What this study did
NCT02581423 · Hoffmann-La Roche
2005-08 – 2007-03 · Colorectal Cancer
What this study did
NCT00216424 · James A. Haley Veterans Administration Hospital
2005-02 – 2007-01 · Colorectal Cancer
What this study did
Gastric Cancer
NCT07829757 · Astellas Pharma Global Development, Inc.
2026-11-30 – 2029-07-31 · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT02380131 · Hebei Medical University
2013-02 – 2017-12 · HER-2 Positive Gastric Cancer, Liver Metastasis
What this study did
NCT01962376 · Hebei Medical University
2013-02 – 2015-04 · Gastric Cancer, Liver Metastasis
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07158164 · Rutgers, The State University of New Jersey
2025-08-27 – 2029-07-07 · Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Gastro-Intestinal Intraepithelial Neoplasia
What this study did
NCT03465202 · Newcastle-upon-Tyne Hospitals NHS Trust
2016-05 – 2019-11 · Breast Cancer, Colorectal Cancer
What this study did
NCT02248571 · iOMEDICO AG
2014-08 – 2017-09-30 · Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast, Hormone Receptor Positive Malignant Neoplasm of Breast
What this study did
NCT00812864 · University Hospital, Limoges
2009-01 – 2012-11 · Breast Cancer, Colorectal Cancer
What this study did
NCT00127933 · Hoffmann-La Roche
2005-08 – 2009-07 · Breast Cancer
What this study did
NCT00121836 · Hoffmann-La Roche
2005-06 – 2008-12 · Breast Cancer
What this study did
NCT00087620 · Hoffmann-La Roche
2004-09 – 2004-10 · Breast Cancer
What this study did
Metastatic Colorectal Cancer
NCT02575378 · Ruijin Hospital
2015-09 – 2018-12 · Metastatic Colorectal Cancer
What this study did
NCT01588990 · Hoffmann-La Roche
2012-06-26 – 2016-09-30 · Colorectal Neoplasms
What this study did
NCT00559676 · Centre Hospital Regional Universitaire de Limoges
2005-03 – 2011-05 · Colorectal Cancer
What this study did
NCT02567331 · Hoffmann-La Roche
2004-10 – 2006-04 · Colorectal Cancer
What this study did
Other / comorbidity
NCT07483060 · Vastra Gotaland Region
2026-03-12 – 2031-12 · Rectal Cancer
What this study did
NCT07801027 · Merck Sharp & Dohme LLC
2026-11-06 – 2030-01-31 · Neoplasm Malignant, Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Carcinoma, Uterine Cervical Neoplasms
What this study did
NCT06217185 · Hebei Medical University Fourth Hospital
2024-01-02 – 2027-06-30 · HER2-positive Breast Cancer, Advanced Breast Cancer
What this study did
NCT04480268 · IRCCS San Raffaele
2020-07-08 – 2026-01-01 · Pancreatic Ductal Adenocarcinoma
What this study did
NCT04269369 · Jessa Hospital
2020-02-18 – 2021-09-30 · Colon Cancer, Stomach Tumor, Anal Tumor, Pancreas Cancer, Esophageal Cancer
What this study did
NCT00871273 · Cambridge University Hospitals NHS Foundation Trust
2009-11 – 2014-10 · Adenocarcinoma of the Stomach
What this study did
NCT00854477 · Cambridge University Hospitals NHS Foundation Trust
2009-11 – 2012-08 · Pancreatic Adenocarcinoma
What this study did
NCT00220168 · Royal Marsden NHS Foundation Trust
started 2003-01 · Upper Gastrointestinal Tumours
What this study did
Early phase / not applicable (57)
Colorectal Cancer
NCT07913516 · Huanfang Fan
2027-01-01 – 2029-12-31 · Advanced Colorectal Cancer, Capecitabine-Related Adverse Reaction
What this study did
NCT07063706 · Faculdade de Farmácia
2022-03-01 – 2024-08-30 · Cancer Colorectal, Cancer Gi, Capecitabine, Pharmaceutical Services, Adverse Drug Reaction (ADR)
What this study did
Gastric Cancer
NCT04891900 · Henan Cancer Hospital
2021-05-10 – 2024-12-01 · Gastric Cancer, Adenocarcinoma of Esophagogastric Junction
What this study did
NCT04281576 · NovoCure Ltd.
2019-12-19 – 2024-06-07 · Gastric Cancer, GastroEsophageal Cancer
What this study did
NCT02358863 · Georgetown University
2015-02 – 2016-11 · Esophageal Cancer, Gastric Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05876065 · Wenjin Yin
2023-06-01 – 2028-02 · Advanced Breast Cancer
What this study did
NCT06602167 · Affiliated Hospital of Qinghai University
2024-10-08 – 2027-12-31 · Capecitabine, Hand-foot Syndrome, Electroacupuncture, Self-administered Acupressure, Breast Cancer, Gastrointestinal Cancers
What this study did
NCT06639178 · Centro di Riferimento Oncologico - Aviano
2024-08-01 – 2026-05-15 · Breast Cancer
What this study did
NCT06857747 · QIAO LI
2025-03-01 – 2026-04-01 · Breast Cancer
What this study did
NCT06156761 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2023-11-28 – 2025-04 · Breast Cancer
What this study did
NCT02028494 · Latin American & Caribbean Society of Medical Oncology
2013-08 – 2019-03 · Breast Cancer
What this study did
NCT02580396 · Royal Marsden NHS Foundation Trust
2016-03-16 – 2018-11-01 · Metastatic Breast Cancer
What this study did
NCT01847599 · Centre Jean Perrin
2011-09-06 – 2017-07-02 · Metastatic Breast Cancer, Colorectal Cancer
What this study did
NCT00953537 · Centre Antoine Lacassagne
2009-01 – 2011-02 · Breast Cancer
What this study did
NCT00156312 · University of Michigan Rogel Cancer Center
2003-07 – 2007-02 · Breast Cancer
What this study did
Metastatic Colorectal Cancer
NCT06115733 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2023-12-28 – 2026-12-31 · Colorectal Carcinoma
What this study did
NCT02043821 · Beijing Chao Yang Hospital
est. completion 2016-01 · Metastatic Colorectal Cancer
What this study did
NCT01280643 · Fox Chase Cancer Center
2010-03 – 2014-05 · Metastatic Colorectal Cancer
What this study did
Pancreatic Cancer
NCT04894643 · EBG MedAustron GmbH
2020-09-14 – 2027-12-31 · Pancreatic Cancer, Proton Therapy
What this study did
NCT06578052 · Junjie Hang
2024-08-28 – 2027-12-31 · Pancreatic Cancer
What this study did
NCT01683422 · Loma Linda University
2013-01-02 – 2019-02-19 · Pancreatic Cancer
What this study did
NCT00524069 · Roswell Park Cancer Institute
2007-01 – 2007-11 · Pancreatic Cancer
What this study did
NCT00159471 · University of Southern California
2005-02 – 2006-07 · Pancreatic Cancer
What this study did
NCT00176735 · University of Michigan Rogel Cancer Center
2001-12 – 2005-08 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT07854964 · Tang-Du Hospital
2026-10-15 – 2031-05-15 · Locally Advanced Rectal Cancer
What this study did
NCT07738042 · Tianjin Medical University Cancer Institute and Hospital
2026-07-31 – 2030-12-31 · Locally Advanced Rectal Cancer (LARC)
What this study did
NCT06434493 · The Christie NHS Foundation Trust
2025-10-03 – 2029-11-01 · Cholangiocarcinoma
What this study did
NCT05838391 · Columbia University
2023-05-18 – 2028-12-31 · Anal Squamous Cell Carcinoma
What this study did
NCT07474103 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-11-30 – 2028-12-31 · Rectal Cancer, Adenocarcinoma
What this study did
NCT07859410 · Anhui Medical University
2026-10-01 – 2028-10-01 · Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05494190 · Eye & ENT Hospital of Fudan University
2022-11-01 – 2027-11 · Hypopharyngeal Carcinoma
What this study did
NCT06894797 · Peking University Cancer Hospital & Institute
2025-04-01 – 2027-10-31 · Locally Advanced Rectal Cancer
What this study did
NCT06463548 · Yunpeng Liu
2024-07-01 – 2026-12-31 · Biliary Tract Carcinoma
What this study did
NCT05877573 · Nanfang Hospital, Southern Medical University
2023-07-01 – 2026-08-01 · Locally Advanced, High-Risk, Rectal Cancer, MSS
What this study did
NCT07334587 · Allama Iqbal Medical College
2025-09-01 – 2026-02-28 · Metastatic Colorectal Carcinoma (mCRC)
What this study did
NCT06349044 · Zhejiang Cancer Hospital
2024-03-20 – 2025-12-31 · Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma, Colorectal Adenocarcinoma
What this study did
NCT05920928 · Tehran University of Medical Sciences
2023-09-23 – 2025-04-01 · Locally Advanced Rectal Carcinoma
What this study did
NCT02232932 · Assistance Publique - Hôpitaux de Paris
2014-03 – 2024-09 · Cholangiocarcinoma
What this study did
NCT06188000 · Universitas Sriwijaya
2023-01-01 – 2024-02-20 · Hand and Foot Skin Reaction, Hand and Foot Syndrome, Capecitabine
What this study did
NCT06246461 · Jingjiang People's Hospital
2022-01-01 – 2024-01-22 · Capecitabine
What this study did
NCT04175899 · Ministry of Health, Malaysia
2019-12-10 – 2021-11 · Solid Tumor, Adult
What this study did
NCT03821454 · Zhejiang Cancer Hospital
2019-02-01 – 2021-02-01 · Breast Cancer
What this study did
NCT03647514 · Zhejiang Cancer Hospital
2018-12-01 – 2020-09-30 · Breast Cancer
What this study did
NCT03634202 · Institut Cancerologie de l'Ouest
2015-05-05 – 2018-12-10 · Rectal Cancer, Metastasis, Radiotherapy
What this study did
NCT01828554 · University of Wisconsin, Madison
2013-06 – 2018-04 · Obesity, Neoplasms
What this study did
NCT01295086 · Odense University Hospital
2011-03 – 2018-01 · Adenocarcinoma
What this study did
NCT01369433 · AVEO Pharmaceuticals, Inc.
2010-06 – 2015-10 · Solid Tumors
What this study did
NCT00535041 · King Faisal Specialist Hospital & Research Center
2007-09 – 2015-09 · Rectal Neoplasms
What this study did
Used as active comparator (154)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (94)
Colorectal Cancer
NCT07412613 · Akeso
2026-04-15 – 2031-03-15 · Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer
What this study did
NCT05863195 · ECOG-ACRIN Cancer Research Group
2024-04-10 – 2029-06-30 · Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
What this study did
NCT03448549 · Peking University Cancer Hospital & Institute
2018-01-01 – 2024-01-01 · Colorectal Cancer Stage III, Adjuvant Chemotherapy
What this study did
NCT01918852 · Dutch Colorectal Cancer Group
2013-12 – 2018-03 · Colorectal Cancer, Metastases
What this study did
NCT00442637 · Dutch Colorectal Cancer Group
2007-01 – 2013-12 · Colorectal Cancer Metastatic
What this study did
NCT00677443 · Samsung Medical Center
2008-06 – 2011-01 · Colorectal Cancer
What this study did
Gastric Cancer
NCT04135781 · Zhejiang Cancer Hospital
2020-03-01 – 2024-10-31 · Stomach Cancer
What this study did
NCT01470742 · Samsung Medical Center
2010-09 – 2015-12 · Gastric Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07060807 · Merck Sharp & Dohme LLC
2025-07-21 – 2033-07-14 · Breast Neoplasms
What this study did
NCT06255392 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-06-12 – 2031-03 · Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer
What this study did
NCT07071337 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2025-07-18 – 2031-02 · Metastatic Breast Cancer
What this study did
NCT04646759 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2020-10-14 – 2030-12-14 · Breast Cancer
What this study did
NCT04263298 · Herui Yao
2018-05-01 – 2030-05-01 · Metastatic Breast Cancer
What this study did
NCT07406542 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-04-01 – 2030-04-01 · Recurrent or Metastatic Breast Cancer
What this study did
NCT06079983 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2023-12-01 – 2029-03-01 · Breast Cancer
What this study did
NCT06561607 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2024-10-11 – 2028-12 · Breast Cancer
What this study did
NCT06018337 · DualityBio Inc.
2024-01-18 – 2028-08 · Metastatic Breast Cancer
What this study did
NCT06383767 · Qilu Pharmaceutical Co., Ltd.
2024-07-11 – 2028-07-31 · Metastatic Breast Cancer
What this study did
NCT05814354 · Jiangsu HengRui Medicine Co., Ltd.
2023-06-30 – 2028-06-30 · Breast Cancer
What this study did
NCT06143553 · Shanghai Yizhong Pharmaceutical Co., Ltd.
2023-09-25 – 2028-06-30 · Metastatic Breast Cancer (MBC)
What this study did
NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd.
2026-03-17 – 2028-06-30 · Locally Advanced or Metastatic Breast Cancer
What this study did
NCT05840211 · Gilead Sciences
2023-05-08 – 2028-04 · Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
What this study did
NCT06268652 · Sun Yat-sen University
2024-01-15 – 2028-01-15 · Breast Cancer, Refractory Breast Carcinoma
What this study did
NCT04400695 · RemeGen Co., Ltd.
2020-09-29 – 2027-12-31 · Breast Cancer
What this study did
NCT06081959 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2023-10-31 – 2027-12-31 · Metastatic Breast Cancer
What this study did
NCT06957886 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-05-15 – 2027-12 · HER2-low Breast Cancer
What this study did
NCT04639986 · Gilead Sciences
2020-11-23 – 2026-12 · Metastatic Breast Cancer
What this study did
NCT04494425 · AstraZeneca
2020-07-24 – 2026-06-19 · Advanced or Metastatic Breast Cancer
What this study did
NCT06313983 · Tianjin Hemay Pharmaceutical Co., Ltd
2022-01-08 – 2026-06 · Breast Cancer
What this study did
NCT04337658 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-07-01 – 2026-04-30 · HER2-positive Breast Cancer
What this study did
NCT03523585 · Daiichi Sankyo
2018-08-01 – 2025-12-23 · Breast Cancer
What this study did
NCT03901339 · Gilead Sciences
2019-05-08 – 2023-10-20 · Metastatic Breast Cancer
What this study did
NCT03462251 · iOMEDICO AG
2018-05-24 – 2022-11-30 · Breast Cancer, Hormone Receptor Positive Tumor, HER 2 Negative Breast Cancer
What this study did
NCT02028507 · Spanish Breast Cancer Research Group
2014-03-13 – 2021-01-11 · Metastatic Breast Cancer
What this study did
NCT00337103 · Eisai Inc.
2006-09-20 – 2017-12-11 · Metastatic Breast Cancer
What this study did
NCT01655992 · Fudan University
2012-01 – 2017-10 · Metastatic Breast Cancer
What this study did
NCT00373113 · Pfizer
2006-11 – 2011-06 · Breast Neoplasms
What this study did
NCT00266799 · Merck Sharp & Dohme LLC
2006-01-13 – 2010-10-18 · Breast Cancer
What this study did
NCT00191152 · Eli Lilly and Company
2002-02 – 2008-11 · Breast Cancer, Breast Neoplasms, Cancer of the Breast
What this study did
NCT00082095 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004-04 – 2005-12 · Metastatic Breast Cancer
What this study did
Metastatic Colorectal Cancer
NCT04607421 · Pfizer
2020-12-21 – 2027-07-29 · Neoplasms
What this study did
NCT03869892 · Institut de Recherches Internationales Servier
2019-03-21 – 2026-12-31 · Metastatic Colorectal Cancer
What this study did
NCT03300609 · University of Southern California
2018-02-27 – 2019-10-03 · Colorectal Adenocarcinoma, RAS Wild Type, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
Pancreatic Cancer
NCT06571461 · CSPC Ouyi Pharmaceutical Co., Ltd.
2024-09 – 2029-03 · Pancreatic Cancer
What this study did
Phase 2/3 (7)
Pancreatic Cancer
NCT04037241 · Sorrento Therapeutics, Inc.
2021-11-01 – 2022-01-01 · Malignant Tumor of Pancreas Metastatic to Liver
What this study did
Other / comorbidity
NCT07935369 · RemeGen Co., Ltd.
2026-11 – 2031-12-31 · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03500380 · RemeGen Co., Ltd.
2018-04-24 – 2024-12-31 · Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
What this study did
NCT01404156 · Dr. Gordon Buduhan
2015-09 – 2023-08 · Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction
What this study did
NCT03873532 · Hutchison Medipharma Limited
2018-07-10 – 2022-03 · Biliary Tract Cancer
What this study did
NCT02213744 · Merrimack Pharmaceuticals
2014-07 – 2017-06 · Breast Cancer, HER2 Positive Breast Cancer
What this study did
Phase 2 (40)
Colorectal Cancer
NCT07562711 · Fudan University
2024-11-01 – 2027-12-31 · ctDNA, Chemotherapy, Colorectal Cancer
What this study did
NCT03813641 · Shenzhen People's Hospital
2019-01-28 – 2021-12-31 · Colorectal Cancer
What this study did
NCT03792269 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2016-01-01 – 2020-12 · Colorectal Cancer Metastatic, Chemotherapy Effect, Chemotherapeutic Toxicity
What this study did
NCT00677144 · Hallym University Medical Center
2008-04 – 2012-04 · Colorectal Neoplasm
What this study did
NCT00551213 · Merck Sharp & Dohme LLC
2007-11-21 – 2009-06-04 · Colorectal Cancer
What this study did
Gastric Cancer
NCT06730373 · Qilu Hospital of Shandong University
2024-10-17 – 2027-12-31 · HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma
What this study did
NCT04937738 · Ukrainian Society of Clinical Oncology
2021-07-21 – 2023-02-01 · Gastric Cancer
What this study did
NCT02623153 · Tianshu Liu
2016-01 – 2019-12 · Gastric Cancer
What this study did
NCT02485834 · Alliance for Clinical Trials in Oncology
2015-11-12 – 2018-08-01 · Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma, Gastric Cancer
What this study did
NCT01070290 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
— · Gastric Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06102824 · Guangdong Provincial People's Hospital
2024-10-01 – 2028-06-30 · HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
NCT02299999 · UNICANCER
2014-04-07 – 2025-12 · Metastatic Breast Cancer
What this study did
NCT03322215 · Theodoros Foukakis
2017-10-24 – 2023-10-31 · Breast Cancer Metastatic
What this study did
NCT02592746 · Samsung Medical Center
2016-06 – 2021-06 · Metastatic Breast Cancer
What this study did
NCT02947061 · Chinese Academy of Medical Sciences
2015-04 – 2019-04 · Breast Cancer Recurrent
What this study did
NCT00777101 · Puma Biotechnology, Inc.
2009-02-04 – 2018-06-03 · Advanced Breast Cancer, Breast Cancer
What this study did
NCT01609127 · Genta Incorporated
2012-05 – 2014-07 · Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer
What this study did
NCT00438100 · Japan Breast Cancer Research Network
2008-04 – 2013-05 · Breast Neoplasms
What this study did
NCT01231802 · Adherex Technologies, Inc.
2011-04 – 2013-01 · Metastatic Breast Cancer
What this study did
NCT01050322 · Latin American Cooperative Oncology Group
2009-11 – 2011-09 · BRMS1, Performance Status Zero to Two for Beginning the Study, Patient With a Maximum of One Chemotherapy, Patient With Progression After Taxanes
What this study did
NCT00732810 · Merck Sharp & Dohme LLC
2008-07 – 2011-06 · Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
What this study did
Metastatic Colorectal Cancer
NCT02743221 · Institut de Recherches Internationales Servier
2016-04-29 – 2020-09-01 · Metastatic Colorectal Cancer
What this study did
NCT02083653 · Symphogen A/S
2014-03-06 – 2017-04-26 · Metastatic Colorectal Cancer
What this study did
NCT00514761 · AstraZeneca
2006-09 – 2008-07 · Metastatic Colorectal Cancer
What this study did
Pancreatic Cancer
NCT01796782 · Fudan University
2013-01 – 2015-12 · Metastatic Pancreatic Cancer
What this study did
NCT00372944 · AstraZeneca
2006-08 – 2008-10 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT05062889 · Gruppo Oncologico del Nord-Ovest
2023-05-17 – 2029-12 · Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
What this study did
NCT06892431 · Shanghai JMT-Bio Inc.
2025-04-01 – 2027-04-30 · Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
What this study did
NCT05126719 · Lepu Biopharma Co., Ltd.
2023-04-06 – 2026-12-30 · Recurrent or Metastatic Nasopharyngeal Carcinoma
What this study did
NCT03872388 · M.D. Anderson Cancer Center
2019-09-23 – 2023-10-19 · Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
What this study did
NCT02017704 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2014-06-12 – 2023-01-31 · Rectal Cancer
What this study did
NCT04745975 · Fudan University
2021-02-01 – 2023-01 · Triple Negative Breast Cancer
What this study did
NCT03079427 · Asan Medical Center
2017-05-15 – 2022-11-15 · Cholangiocarcinoma, Biliary Tract Cancer, Adjuvant Chemotherapy, Capecitabine, Gemcitabine, Cisplatin
What this study did
NCT01997333 · Celldex Therapeutics
2013-11 – 2018-08-07 · Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
What this study did
NCT02216149 · Heikki Joensuu
2015-01 – 2018-08 · Esophagus Cancer, Stomach Cancer, Small Bowel Cancer, Colon Cancer, Rectum Cancer
What this study did
NCT02022852 · Harbin Medical University
2013-07 – 2018-01 · Rectal Cancer
What this study did
NCT01013740 · Novartis Pharmaceuticals
2009-11-25 – 2016-03-01 · Cancer
What this study did
Phase 1/2 (4)
HR+/HER2- Metastatic Breast Cancer
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
Metastatic Colorectal Cancer
NCT06195670 · Zhejiang Cancer Hospital
2024-01 – 2027-01 · CRC, Metastatic Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
What this study did
Pancreatic Cancer
Other / comorbidity
NCT04177602 · Universitätsklinikum Hamburg-Eppendorf
2019-11-04 – 2022-09-02 · Locally Advanced Rectal Cancer
What this study did
Phase 1 (1)
Other / comorbidity
NCT01471847 · Novartis Pharmaceuticals
2012-02 – 2012-06 · Locally Advance Breast Cancer (LABC), Metastatic Breast Cancer (MBC)
What this study did
Phase 4 (5)
Colorectal Cancer
NCT07094893 · Gruppo Oncologico del Nord-Ovest
2026-09-15 – 2030-03 · Colorectal Cancer
What this study did
NCT06090994 · Fudan University
2024-10-18 – 2029-11 · Colorectal Cancer
What this study did
Pancreatic Cancer
NCT06387368 · Xi'an Jiaotong University
2024-05 – 2028-08 · Pancreatic Cancer Non-resectable
What this study did
Other / comorbidity
Early phase / not applicable (3)
HR+/HER2- Metastatic Breast Cancer
Other / comorbidity
NCT07156058 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2023-01-01 – 2025-12-31 · Biliary Tract Cancer
What this study did
NCT03042000 · Peking Union Medical College Hospital
2017-02 – 2021-12 · Rectal Cancer, Adenocarcinoma, Neoadjuvant Chemoradiation
What this study did
Appears in other studies (100)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (51)
Colorectal Cancer
NCT00766155 · European Organisation for Research and Treatment of Cancer - EORTC
2008-08 – 2011-09 · Colorectal Cancer
What this study did
Gastric Cancer
NCT07673887 · Astellas Pharma Global Development, Inc.
2026-07-28 – 2031-02-28 · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT07818070 · Ono Pharmaceutical Co., Ltd.
2027-02 – 2031-01 · Gastric Cancer, Esophagogastric Junction Cancer, Esophageal Adenocarcinoma
What this study did
NCT06901531 · Astellas Pharma Global Development, Inc.
2025-05-22 – 2028-09-30 · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT06177041 · FutureGen Biopharmaceutical (Beijing) Co., Ltd
2023-12-25 – 2027-04-11 · Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT00680901 · Novartis Pharmaceuticals
2008-06-04 – 2024-10-03 · Neoplasms, Gastrointestinal Tract
What this study did
NCT03006705 · Ono Pharmaceutical Co., Ltd.
2017-01-31 – 2023-03-31 · Gastric Cancer
What this study did
NCT03745170 · Innovent Biologics (Suzhou) Co. Ltd.
2018-12-19 – 2022-10-21 · Gastric Cancer
What this study did
NCT02137343 · Amgen
2014-07 – 2015-06 · Gastric Cancer
What this study did
NCT00548548 · Genentech, Inc.
2007-09 – 2013-11 · Adenocarcinoma
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT01953003 · Pierre Fabre Medicament
2013-09 – 2017-07 · Malignant Neoplasm of Breast
What this study did
NCT00148876 · GBG Forschungs GmbH
2003-09 – 2011-01 · Breast Cancer
What this study did
NCT00078572 · GlaxoSmithKline
2004-03 – 2010-02 · Breast Cancer
What this study did
NCT00305643 · M.D. Anderson Cancer Center
2006-02 – 2008-10 · Breast Cancer, Colorectal Cancer, Pain
What this study did
Metastatic Colorectal Cancer
NCT07025239 · Qilu Pharmaceutical Co., Ltd.
2025-07 – 2029-07 · Metastatic Colorectal Cancer
What this study did
NCT00484939 · Hoffmann-La Roche
2007-07 – 2013-03 · Colorectal Cancer
What this study did
Pancreatic Cancer
NCT02117479 · Incyte Corporation
2014-03 – 2016-12 · Pancreatic Cancer
What this study did
NCT02119663 · Incyte Corporation
2014-06 – 2016-10 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT03801876 · NRG Oncology
2019-06-26 – 2036-11-07 · Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Thoracic Esophagus Squamous Cell Carcinoma
What this study did
NCT04335669 · Lund University Hospital
2019-12-20 – 2035-09 · Breast Cancer, Triple Negative Breast Neoplasms
What this study did
NCT04095299 · Vejle Hospital
2020-01-20 – 2033-12 · Cancer of Rectum
What this study did
NCT07917468 · Innovent Biologics (Suzhou) Co. Ltd.
2026-11-25 – 2031-11-24 · Locally Advanced Rectal Cancer
What this study did
NCT06561763 · Sun Yat-sen University
2024-08-20 – 2031-08-20 · High Risk Locally Advanced Nasopharyngeal Carcinoma
What this study did
NCT06246344 · Shandong Cancer Hospital and Institute
2023-12-01 – 2030-12-01 · Rectal Cancer
What this study did
NCT07118527 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-08-18 – 2030-10 · Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07132008 · First Affiliated Hospital of Guangxi Medical University
2025-10-01 – 2030-09-30 · Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
What this study did
NCT02505750 · Centre Antoine Lacassagne
2015-06-24 – 2030-06 · Rectal Neoplasms
What this study did
NCT06109779 · AstraZeneca
2023-12-04 – 2030-05-03 · Biliary Tract Cancer
What this study did
NCT05342792 · Sun Yat-sen University
2022-04-17 – 2029-06 · Nasopharyngeal Carcinoma
What this study did
NCT06622057 · InnoPharmax Inc.
2026-06-09 – 2028-12-31 · Biliary Tract Cancer (BTC)
What this study did
NCT06206733 · AskGene Pharma, Inc.
2024-01-25 – 2028-12-30 · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
What this study did
NCT05717764 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
2023-02 – 2027-09 · Recurrent Metastatic Nasopharyngeal Carcinoma
What this study did
NCT04550260 · AstraZeneca
2020-10-19 – 2027-06-30 · Esophageal Squamous Cell Carcinoma
What this study did
NCT03653507 · Astellas Pharma Global Development, Inc.
2018-11-28 – 2027-03-31 · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT06017583 · Yong Zhang,MD
2023-09-01 – 2026-08-31 · Rectal Neoplasms
What this study did
NCT03371017 · Hoffmann-La Roche
2018-01-11 – 2024-10-23 · Triple Negative Breast Neoplasms
What this study did
NCT03777657 · BeiGene
2018-12-13 – 2024-08-27 · Gastric, or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03783442 · BeiGene
2018-12-11 – 2024-08-22 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT04103697 · Blokhin's Russian Cancer Research Center
2019-08-01 – 2024-08 · Rectal Neoplasms Malignant, Rectum Carcinoma, Rectal Cancer
What this study did
NCT03779035 · Tianjin Medical University Cancer Institute and Hospital
2018-12-15 – 2023-12-31 · Cholangiocarcinoma, Gall Bladder Carcinoma
What this study did
NCT03802591 · CStone Pharmaceuticals
2019-03-28 – 2023-09-22 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT02973737 · Jiangsu HengRui Medicine Co., Ltd.
2016-07-20 – 2023-06 · HER2 Positive Metastatic Breast Cancer
What this study did
NCT03970694 · Sun Yat-sen University
2019-05-11 – 2022-06-05 · Colon Cancer
What this study did
NCT02314117 · Eli Lilly and Company
2015-01-20 – 2020-08-14 · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03579758 · Emory University
2019-04-03 – 2020-06-01 · Stage I Gallbladder Cancer AJCC v8, Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8
What this study did
Phase 2/3 (5)
Colorectal Cancer
NCT02529774 · Ye Xu
2015-09 – 2021-09 · Resected Liver Metastases From Colorectal Cancer
What this study did
Gastric Cancer
NCT01924819 · Australasian Gastro-Intestinal Trials Group
2009-09 – 2026-12-31 · Gastric Cancer
What this study did
Other / comorbidity
NCT07251062 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2025-12-30 – 2030-12-30 · Esophageal Squamous Cell Carcinoma
What this study did
NCT06037980 · Gruppo Oncologico del Nord-Ovest
2023-11-07 – 2029-01 · Biliary Tract Cancer, Cholangiocarcinoma
What this study did
NCT03093870 · ASLAN Pharmaceuticals
2017-07-04 – 2020-04-17 · Biliary Tract Cancer
What this study did
Phase 2 (37)
Colorectal Cancer
NCT02688023 · Chinese Academy of Medical Sciences
2014-03 – 2019-12 · Colorectal Cancer
What this study did
NCT01993472 · Gu Yanhong
2013-11 – 2016-12 · Colorectal Neoplasms
What this study did
Gastric Cancer
NCT01711242 · xie congying
2012-01 – 2021-01 · Gastric Cancer
What this study did
NCT00737438 · Memorial Sloan Kettering Cancer Center
2008-08 – 2015-02 · Esophageal Cancer, Gastric Cancer
What this study did
NCT01123473 · European Organisation for Research and Treatment of Cancer - EORTC
2010-12 – 2014-09 · Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer
What this study did
NCT01573468 · Genta Incorporated
2012-04 – 2014-08 · Gastric Carcinoma
What this study did
NCT00743964 · Samsung Medical Center
2008-04 – 2009-10 · Advanced Gastric Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05163223 · Aston Sci. Inc.
2022-02-28 – 2024-05-31 · Breast Cancer
What this study did
NCT02229149 · US Oncology Research
2014-12 – 2022-01 · Breast Neoplasms, Malignant Tumor of the Breast
What this study did
NCT02120417 · Incyte Corporation
2014-05 – 2017-01 · Breast Cancer
What this study did
NCT01067989 · HaEmek Medical Center, Israel
2010-03 – 2014-04 · Chemotherapy, Breast Cancer, Metastatic
What this study did
NCT00657137 · Tragara Pharmaceuticals, Inc.
2008-04 – 2009-09 · Breast Cancer
What this study did
NCT00437294 · Eli Lilly and Company
2007-03 – 2009-03 · Breast Cancer
What this study did
Metastatic Colorectal Cancer
NCT02873195 · Academic and Community Cancer Research United
2017-07-07 – 2023-12-01 · Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
Pancreatic Cancer
NCT04089150 · Australasian Gastro-Intestinal Trials Group
2019-10-01 – 2023-08-30 · Pancreatic Cancer
What this study did
NCT01423604 · Incyte Corporation
2011-07 – 2016-11 · Pancreatic Cancer
What this study did
Other / comorbidity
NCT06992336 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-04-10 – 2036-01-01 · Breast Cancer
What this study did
NCT07824869 · Shanghai Henlius Biotech
2026-10-31 – 2029-12-04 · HER2 + Breast Cancer
What this study did
NCT05201859 · Sun Yat-sen University
2022-05-17 – 2029-03-02 · Nasopharyngeal Carcinoma
What this study did
NCT05358704 · Rutgers, The State University of New Jersey
2022-05-13 – 2028-01-30 · Cancer of Rectum
What this study did
NCT06685289 · The First Affiliated Hospital with Nanjing Medical University
2024-11-15 – 2027-11-15 · Biliary Malignant Tumors
What this study did
NCT06055166 · Chongqing University Cancer Hospital
2023-11-01 – 2026-05-31 · PARP Inhibitor for Esophageal Squamous Cell Carcinoma
What this study did
NCT06247956 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2024-03-11 – 2025-12-30 · Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma
What this study did
NCT05390476 · wang shusen
2022-08-01 – 2024-12-01 · Triple Negative Breast Cancer
What this study did
NCT04508452 · First Affiliated Hospital of Zhejiang University
2020-05-18 – 2023-06-01 · Unresectable Metastatic Colorectal Carcinoma
What this study did
NCT04394598 · Fudan University
2020-03-01 – 2022-12-01 · Locally Advanced Rectal Cancer
What this study did
NCT02614794 · Seagen Inc.
2016-01-28 – 2022-08-11 · HER2 Positive Breast Cancer
What this study did
NCT03609489 · First Affiliated Hospital of Guangxi Medical University
2018-09-10 – 2021-12-25 · Biliary Carcinoma
What this study did
NCT03775928 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2018-12-18 – 2021-10-01 · Triple-negative Breast Cancer
What this study did
NCT02473094 · University of Campinas, Brazil
2015-07 – 2016-02 · Rectal Neoplasms, Adenocarcinoma, Carcinoma
What this study did
NCT01641406 · Auxilio Mutuo Cancer Center
2011-03 – 2013-03 · Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma, Inflammatory Breast Carcinoma
What this study did
NCT00398879 · AEterna Zentaris
2005-08 – 2011-10 · Colon Cancer
What this study did
Phase 1/2 (3)
Colorectal Cancer
NCT06253871 · Iambic Therapeutics, Inc
2024-03-25 – 2028-12 · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
What this study did
Gastric Cancer
NCT02795988 · Imugene Limited
2017-08-30 – 2024-03-20 · Gastrointestinal Neoplasms, Adenocarcinoma
What this study did
Other / comorbidity
NCT05249101 · CG Pharmaceuticals, Inc
2022-08-15 – 2026-07 · Metastatic Pancreatic Adenocarcinoma
What this study did
Phase 4 (1)
Early phase / not applicable (3)
Gastric Cancer
NCT06158919 · Fudan University
2023-11-20 – 2026-11-20 · Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
What this study did
Other / comorbidity
NCT04194957 · The Netherlands Cancer Institute
2020-01-15 – 2021-01 · Neoplasms
What this study did
NCT02324452 · The Netherlands Cancer Institute
2015-03 – 2018-03 · Neoplasms
What this study did

Competitive landscape

This drug's own stage for Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Capecitabine: this drugApprovedSmall moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis)
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890Phase 3Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 3Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 2/3PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
IBI305Phase 2Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
SirexatamabPhase 2Monoclonal antibodyDKK1 (Dickkopf-1)not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
NC410
Phase 1/2(overall)
Protein / enzyme therapeuticCollagen (LAIR-1 ligands)not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T Cell
Phase 1(overall)
Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
PI3Kalpha Precision Therapy
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(286 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Capecitabine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (31)
November 2026 (9)
Phase 2Rectal CancerActive not recruiting
Est. primary completion 2026-11 · NCT02008656 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast Cancer, Breast CancerRecruiting
Est. primary completion 2026-11 · NCT04768426 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaActive not recruiting
Est. primary completion 2026-11 · NCT06118333 · CT.gov ↗
What to watch
Phase 2GI CancersEnrolling by invitation
Est. primary completion 2026-11 · NCT06648785 · CT.gov ↗
What to watch
Phase 2MSI-H/dMMR Locally Advanced Rectal AdenocarcinomaRecruiting
Est. primary completion 2026-11 · NCT07750951 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2026-11-27 · NCT06885385 · CT.gov ↗
What to watch
Phase 2Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, Adult, Endometrial CancerRecruiting
Est. primary completion 2026-11-30 · NCT04165772 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2026-11-30 · NCT05093907 · CT.gov ↗
What to watch
Phase 2Gastrointestinal Neuroendocrine CarcinomaRecruiting
Est. primary completion 2026-11-30 · NCT06070740 · CT.gov ↗
What to watch
December 2026 (22)
Phase 1/2Colorectal CancerActive not recruiting
Est. primary completion 2026-12 · NCT05700656 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT05800275 · CT.gov ↗
What to watch
Phase 1Gastrointestinal CancerRecruiting
Est. primary completion 2026-12 · NCT06065371 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT06202261 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2026-12 · NCT06942767 · CT.gov ↗
What to watch
Phase 2Rectal Cancer PatientsRecruiting
Est. primary completion 2026-12-01 · NCT06647680 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer With Liver MetastasesRecruiting
Est. primary completion 2026-12-01 · NCT06787183 · CT.gov ↗
What to watch
Early phase / not applicableColorectal CancerNot yet recruiting
Est. primary completion 2026-12-15 · NCT06115733 · CT.gov ↗
What to watch
Phase 3Colorectal CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT05171660 · CT.gov ↗
What to watch
Phase 2pMMR, MSS, MSI-L, Locally Advanced Rectal CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT05731726 · CT.gov ↗
What to watch
Phase 2Rectal CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT01941641 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2026-12-31 · NCT03161522 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT03756298 · CT.gov ↗
What to watch
Early phase / not applicablePancreatic CancerRecruiting
Est. primary completion 2026-12-31 · NCT04894643 · CT.gov ↗
What to watch
Early phase / not applicableAnal Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05838391 · CT.gov ↗
What to watch
Phase 2HER2-positive Breast Cancer, LMDRecruiting
Est. primary completion 2026-12-31 · NCT06016387 · CT.gov ↗
What to watch
Phase 3Triple-negative Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06533384 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2026-12-31 · NCT06555471 · CT.gov ↗
What to watch
Phase 2Gallbladder Cancer, Hilar Cholangiocarcinoma, Distal CholangiocarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT06717464 · CT.gov ↗
What to watch
Phase 2Rectal CancerRecruiting
Est. primary completion 2026-12-31 · NCT07068763 · CT.gov ↗
What to watch
Phase 2Rectal Cancer, Radiotherapy, Immunotherapy, ChemotherapyRecruiting
Est. primary completion 2026-12-31 · NCT07239466 · CT.gov ↗
What to watch
Phase 2Combined Hepatocellular-cholangiocarcinoma, Liver NeoplasmsNot yet recruiting
Est. primary completion 2026-12-31 · NCT07243951 · CT.gov ↗
What to watch
2027 (98)
January 2027 (6)
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2027-01 · NCT06328738 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-01 · NCT06741644 · CT.gov ↗
What to watch
Phase 2Biliary Tract Neoplasms ImmunotherapyRecruiting
Est. primary completion 2027-01-01 · NCT07679399 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-01-15 · NCT06759090 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-15 · NCT06764940 · CT.gov ↗
What to watch
Phase 1Locally Advanced Rectal Cancer (LARC)Active not recruiting
Est. primary completion 2027-01-30 · NCT06459869 · CT.gov ↗
What to watch
February 2027 (5)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-02 · NCT07229846 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-02-20 · NCT06239727 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-02-26 · NCT06208410 · CT.gov ↗
What to watch
Phase 2Liver MetastasesRecruiting
Est. primary completion 2027-02-28 · NCT05062317 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-02-28 · NCT05929885 · CT.gov ↗
What to watch
March 2027 (4)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-03-01 · NCT05172518 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-03-30 · NCT04595565 · CT.gov ↗
What to watch
Phase 2Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8 …Recruiting
Est. primary completion 2027-03-31 · NCT05040360 · CT.gov ↗
What to watch
Phase 2Rectal CancerRecruiting
Est. primary completion 2027-03-31 · NCT07104604 · CT.gov ↗
What to watch
April 2027 (9)
Phase 2Pancreatic CancerActive not recruiting
Est. primary completion 2027-04 · NCT03523312 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗
What to watch
Phase 2Solid Tumors, Children, AdolescentsRecruiting
Est. primary completion 2027-04-01 · NCT06761417 · CT.gov ↗
What to watch
Phase 1/2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-04-01 · NCT06888674 · CT.gov ↗
What to watch
Phase 1Rectal AdenocarcinomaRecruiting
Est. primary completion 2027-04-14 · NCT04808323 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-04-14 · NCT06247995 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal CancerNot yet recruiting
Est. primary completion 2027-04-24 · NCT05794750 · CT.gov ↗
What to watch
Phase 1/2Gastrointestinal CancerRecruiting
Est. primary completion 2027-04-30 · NCT07056777 · CT.gov ↗
What to watch
Phase 2Advanced Rectal CancerRecruiting
Est. primary completion 2027-04-30 · NCT07281157 · CT.gov ↗
What to watch
May 2027 (4)
Phase 2Advanced Rectal CancerRecruiting
Est. primary completion 2027-05-01 · NCT05228431 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-05-04 · NCT04379596 · CT.gov ↗
What to watch
Phase 2/3Colorectal CancerRecruiting
Est. primary completion 2027-05-12 · NCT07462143 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-05-30 · NCT07570914 · CT.gov ↗
What to watch
June 2027 (8)
Early phase / not applicableHR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06 · NCT05876065 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2027-06 · NCT07653685 · CT.gov ↗
What to watch
Phase 2Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid NeoplasmRecruiting
Est. primary completion 2027-06-01 · NCT03907475 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2027-06-01 · NCT06532006 · CT.gov ↗
What to watch
Phase 1/2Advanced CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT04495296 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2027-06-30 · NCT05803382 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT06942234 · CT.gov ↗
What to watch
Phase 1/2Pancreatic CancerRecruiting
Est. primary completion 2027-06-30 · NCT07692750 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-07-06 · NCT07051785 · CT.gov ↗
What to watch
Phase 4HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-07 · NCT07158164 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2027-07-21 · NCT04997837 · CT.gov ↗
What to watch
Early phase / not applicableHR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-30 · NCT06602167 · CT.gov ↗
What to watch
August 2027 (7)
Phase 2/3Adenocarcinoma of the RectumActive not recruiting
Est. primary completion 2027-08 · NCT02945566 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-08 · NCT04501523 · CT.gov ↗
What to watch
Phase 3Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3, Neuroendocrine Gastroenteropancreatic TumourRecruiting
Est. primary completion 2027-08-07 · NCT07185672 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal CancerRecruiting
Est. primary completion 2027-08-10 · NCT07469306 · CT.gov ↗
What to watch
Phase 2Colon CancerNot yet recruiting
Est. primary completion 2027-08-30 · NCT06790212 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-08-31 · NCT05693766 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer, Neoadjuvant TherapyRecruiting
Est. primary completion 2027-08-31 · NCT07150949 · CT.gov ↗
What to watch
September 2027 (12)
Phase 2Metastatic Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2027-09 · NCT05484375 · CT.gov ↗
What to watch
Phase 2Colorectal CarcinomaRecruiting
Est. primary completion 2027-09 · NCT06991465 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2027-09 · NCT07215936 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2027-09-01 · NCT05851924 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-09-01 · NCT05976568 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal CancerRecruiting
Est. primary completion 2027-09-01 · NCT06204094 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-09-01 · NCT06560528 · CT.gov ↗
What to watch
Early phase / not applicablePancreatic CancerRecruiting
Est. primary completion 2027-09-01 · NCT06578052 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-09-01 · NCT06788171 · CT.gov ↗
What to watch
Phase 2Resectable Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2027-09-04 · NCT05265208 · CT.gov ↗
What to watch
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2027-09-27 · NCT01061515 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT02955940 · CT.gov ↗
What to watch
October 2027 (12)
Phase 1/2Solid TumorRecruiting
Est. primary completion 2027-10 · NCT07140393 · CT.gov ↗
What to watch
Phase 2CholangiocarcinomaNot yet recruiting
Est. primary completion 2027-10 · NCT07296666 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine CarcinomaActive not recruiting
Est. primary completion 2027-10-01 · NCT05247905 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-10-01 · NCT05489211 · CT.gov ↗
What to watch
Phase 2Rectal Cancer Patients, Locally Advanced Rectal Cancer (LARC)Recruiting
Est. primary completion 2027-10-01 · NCT07898865 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsActive not recruiting
Est. primary completion 2027-10-14 · NCT06544655 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-10-20 · NCT07407465 · CT.gov ↗
What to watch
Phase 3Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-10-30 · NCT07043400 · CT.gov ↗
What to watch
Phase 1Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2027-10-31 · NCT04615013 · CT.gov ↗
What to watch
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2027-10-31 · NCT06547385 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-10-31 · NCT07828756 · CT.gov ↗
What to watch
Phase 2Rectal Cancer, Radiotherapy, Immunotherapy, ChemotherapyNot yet recruiting
Est. primary completion 2027-10-31 · NCT07847229 · CT.gov ↗
What to watch
November 2027 (7)
Early phase / not applicableHypopharyngeal CarcinomaRecruiting
Est. primary completion 2027-11 · NCT05494190 · CT.gov ↗
What to watch
Phase 2Pseudomyxoma PeritoneiRecruiting
Est. primary completion 2027-11 · NCT06800391 · CT.gov ↗
What to watch
Phase 2Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8Recruiting
Est. primary completion 2027-11-05 · NCT06780787 · CT.gov ↗
What to watch
Phase 2Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2027-11-09 · NCT07069712 · CT.gov ↗
What to watch
Phase 3Gastric / Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-11-17 · NCT07449780 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-11-30 · NCT05702229 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-11-30 · NCT06123338 · CT.gov ↗
What to watch
December 2027 (20)
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-12 · NCT05671822 · CT.gov ↗
What to watch
Phase 2Breast Cancer, MetastaticRecruiting
Est. primary completion 2027-12 · NCT07007559 · CT.gov ↗
What to watch
Phase 1/2Rectal CancerRecruiting
Est. primary completion 2027-12 · NCT07561060 · CT.gov ↗
What to watch
Phase 1/2GC/GEJCNot yet recruiting
Est. primary completion 2027-12 · NCT07680569 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal Carcinoma, Maintenance TherapyActive not recruiting
Est. primary completion 2027-12-20 · NCT05869227 · CT.gov ↗
What to watch
Phase 2Adenocarcinoma of Small Intestine, Appendix Carcinoma, MetastaticRecruiting
Est. primary completion 2027-12-30 · NCT05472948 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2027-12-30 · NCT05785741 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-12-30 · NCT07503756 · CT.gov ↗
What to watch
Phase 2Pan-tumorRecruiting
Est. primary completion 2027-12-31 · NCT04566380 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsActive not recruiting
Est. primary completion 2027-12-31 · NCT05502393 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Carcinoma, Local RecurrenceRecruiting
Est. primary completion 2027-12-31 · NCT07331428 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumor CancerRecruiting
Est. primary completion 2027-12-31 · NCT07477743 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-12-31 · NCT07490262 · CT.gov ↗
What to watch
Phase 1/2HER 2 Positive Advanced Breast Cancer, Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07494448 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-12-31 · NCT07562659 · CT.gov ↗
What to watch
Phase 2Recurrent/ Metastatic NPCRecruiting
Est. primary completion 2027-12-31 · NCT07690787 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07691632 · CT.gov ↗
What to watch
Early phase / not applicableLocally Advanced Rectal Cancer (LARC)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07738042 · CT.gov ↗
What to watch
Phase 2Early Low Rectal CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07837362 · CT.gov ↗
What to watch
Phase 3Early Low Rectal CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07933679 · CT.gov ↗
What to watch
2028 (71)
January 2028 (9)
Phase 1Locally-advanced Rectal CancerRecruiting
Est. primary completion 2028-01-01 · NCT05912075 · CT.gov ↗
What to watch
Phase 2/3NPC, HNSCC, Recurrence, MetastasisNot yet recruiting
Est. primary completion 2028-01-01 · NCT06719479 · CT.gov ↗
What to watch
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
Phase 3Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy, ImmunotherapyRecruiting
Est. primary completion 2028-01-01 · NCT07113275 · CT.gov ↗
What to watch
Phase 2Head Neck Cancer, Mouth Cancer, Throat Cancer, Larynx Cancer, Skin Cancer FaceNot yet recruiting
Est. primary completion 2028-01-01 · NCT07254962 · CT.gov ↗
What to watch
Phase 2Rectal CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT07774754 · CT.gov ↗
What to watch
Phase 2/3HER2-positive Breast Cancer, Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01-16 · NCT07366840 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Breast Cancer, Breast NeoplasmsNot yet recruiting
Est. primary completion 2028-01-30 · NCT07691333 · CT.gov ↗
What to watch
Phase 1Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2028-01-31 · NCT07024615 · CT.gov ↗
What to watch
February 2028 (2)
Phase 1Triple Negative Breast Cancer (TNBC)Recruiting
Est. primary completion 2028-02 · NCT07652242 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2028-02-01 · NCT06888843 · CT.gov ↗
What to watch
March 2028 (5)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-03-01 · NCT07684456 · CT.gov ↗
What to watch
Phase 2Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant TherapyRecruiting
Est. primary completion 2028-03-01 · NCT07847710 · CT.gov ↗
What to watch
Phase 3Gastric CancerActive not recruiting
Est. primary completion 2028-03-31 · NCT04248452 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2028-03-31 · NCT05034887 · CT.gov ↗
What to watch
Early phase / not applicableRectal Cancer, AdenocarcinomaRecruiting
Est. primary completion 2028-03-31 · NCT07474103 · CT.gov ↗
What to watch
April 2028 (6)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-04 · NCT07503639 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2028-04 · NCT07551778 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-04-01 · NCT07515625 · CT.gov ↗
What to watch
Phase 3Metastatic HER2-positive Breast CancerRecruiting
Est. primary completion 2028-04-28 · NCT06435429 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2028-04-30 · NCT06839105 · CT.gov ↗
What to watch
Phase 1/2Malignant Digestive System NeoplasmRecruiting
Est. primary completion 2028-04-30 · NCT07456852 · CT.gov ↗
What to watch
May 2028 (7)
Phase 1Advanced Malignant Solid TumorsRecruiting
Est. primary completion 2028-05 · NCT07824934 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-05-09 · NCT07621484 · CT.gov ↗
What to watch
Phase 3Gastric CarcinomaNot yet recruiting
Est. primary completion 2028-05-15 · NCT06944496 · CT.gov ↗
What to watch
Phase 2Colon CancerRecruiting
Est. primary completion 2028-05-30 · NCT06949111 · CT.gov ↗
What to watch
Phase 2Advanced Solid TumourRecruiting
Est. primary completion 2028-05-30 · NCT07390383 · CT.gov ↗
What to watch
Phase 1Pancreatic CancerRecruiting
Est. primary completion 2028-05-31 · NCT05365581 · CT.gov ↗
What to watch
Phase 3Esophageal Cancer, ChemoradiotherapyRecruiting
Est. primary completion 2028-05-31 · NCT07177794 · CT.gov ↗
What to watch
June 2028 (9)
Phase 1/2Glioblastoma Multiforme (GBM), Glioblastoma, Glioma of Brain, Glioblastoma, Adult, Brain Tumor, Brain Tumor, Primary, Brain Tumor Adult …Recruiting
Est. primary completion 2028-06 · NCT03213002 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06 · NCT06105684 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07685704 · CT.gov ↗
What to watch
Phase 2Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-01 · NCT06598046 · CT.gov ↗
What to watch
Phase 3HER2-positive Breast CancerRecruiting
Est. primary completion 2028-06-08 · NCT06992882 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2028-06-30 · NCT01935778 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-06-30 · NCT06998771 · CT.gov ↗
What to watch
Phase 2Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-06-30 · NCT07609667 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerNot yet recruiting
Est. primary completion 2028-06-30 · NCT07841873 · CT.gov ↗
What to watch
July 2028 (6)
Phase 2Neuroendocrine Tumor Grade 2, Neuroendocrine TumorsRecruiting
Est. primary completion 2028-07-01 · NCT04339036 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal Cancer (LARC)Not yet recruiting
Est. primary completion 2028-07-01 · NCT07381777 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-07-01 · NCT07655661 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-07-30 · NCT07243938 · CT.gov ↗
What to watch
Phase 2HER2-positive Breast Cancer, Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-07-31 · NCT07019337 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-07-31 · NCT07112053 · CT.gov ↗
What to watch
August 2028 (3)
Phase 2Triple Negative Breast NeoplasmsRecruiting
Est. primary completion 2028-08 · NCT05973864 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast CancerNot yet recruiting
Est. primary completion 2028-08 · NCT07681297 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-08-31 · NCT07134101 · CT.gov ↗
What to watch
September 2028 (5)
Phase 3Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2028-09 · NCT07716449 · CT.gov ↗
What to watch
Phase 2/3Breast CancerRecruiting
Est. primary completion 2028-09-01 · NCT04803539 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2028-09-01 · NCT07833241 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma of the Anal CanalNot yet recruiting
Est. primary completion 2028-09-19 · NCT07800000 · CT.gov ↗
What to watch
Early phase / not applicableColorectal CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT07913516 · CT.gov ↗
What to watch
October 2028 (4)
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2028-10 · NCT06093061 · CT.gov ↗
What to watch
Early phase / not applicableGastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT07859410 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer (BTC), Surgery, RadiotherapyRecruiting
Est. primary completion 2028-10-08 · NCT07893392 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-10-30 · NCT06630130 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2028-11-20 · NCT06112379 · CT.gov ↗
What to watch
December 2028 (14)
Phase 2Pancreatic CancerActive not recruiting
Est. primary completion 2028-12 · NCT03351296 · CT.gov ↗
What to watch
Phase 2/3Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage IIIRecruiting
Est. primary completion 2028-12 · NCT05288777 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07737600 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07874425 · CT.gov ↗
What to watch
Phase 2Advanced Solid TumourRecruiting
Est. primary completion 2028-12-26 · NCT07331155 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2028-12-30 · NCT07384234 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12-30 · NCT07709767 · CT.gov ↗
What to watch
Phase 1Gastric CancerActive not recruiting
Est. primary completion 2028-12-31 · NCT04523818 · CT.gov ↗
What to watch
Phase 2Recurrent Rectal CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT06751394 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06787339 · CT.gov ↗
What to watch
Phase 1Colorectal CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT06963502 · CT.gov ↗
What to watch
Phase 4Rectal CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07483060 · CT.gov ↗
What to watch
Phase 2Late-stage Resectable Esophageal Squamous CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07622797 · CT.gov ↗
What to watch
Phase 3Gastric CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07677293 · CT.gov ↗
What to watch
2029 (37)
January 2029 (4)
Phase 2Rectal CancerRecruiting
Est. primary completion 2029-01 · NCT07622017 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2029-01-08 · NCT06324357 · CT.gov ↗
What to watch
Phase 2Breast Cancer, HER2-positive Breast CancerNot yet recruiting
Est. primary completion 2029-01-31 · NCT07417241 · CT.gov ↗
What to watch
Phase 3Gastric AdenocarcinomaRecruiting
Est. primary completion 2029-01-31 · NCT07584135 · CT.gov ↗
What to watch
February 2029 (5)
Phase 1/2Locally Advanced / Metastatic Solid TumorsRecruiting
Est. primary completion 2029-02 · NCT07335497 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2029-02-01 · NCT07395063 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruiting
Est. primary completion 2029-02-20 · NCT05797077 · CT.gov ↗
What to watch
Phase 1Solid Tumors, Advanced Solid TumorsNot yet recruiting
Est. primary completion 2029-02-27 · NCT07904845 · CT.gov ↗
What to watch
Phase 2Extrahepatic Cholangiocarcinoma and Gallbladder CarcinomaRecruiting
Est. primary completion 2029-02-28 · NCT07636824 · CT.gov ↗
What to watch
March 2029 (2)
Phase 3Anal Squamous Cell Carcinoma, Limited-stageRecruiting
Est. primary completion 2029-03 · NCT07692152 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2029-03-10 · NCT06313567 · CT.gov ↗
What to watch
April 2029 (4)
Phase 2Gastric CancerRecruiting
Est. primary completion 2029-04-01 · NCT07007182 · CT.gov ↗
What to watch
Phase 2Rectal CancerNot yet recruiting
Est. primary completion 2029-04-10 · NCT07509424 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2029-04-27 · NCT06764875 · CT.gov ↗
What to watch
Phase 3Colorectal CancerNot yet recruiting
Est. primary completion 2029-04-28 · NCT07885384 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2/3HER2-positive Breast CancerRecruiting
Est. primary completion 2029-05-01 · NCT07413939 · CT.gov ↗
What to watch
June 2029 (3)
Phase 2Triple Negative Breast CancerRecruiting
Est. primary completion 2029-06 · NCT06245889 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast CancerRecruiting
Est. primary completion 2029-06 · NCT06291064 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Carcinoma (NPC)Not yet recruiting
Est. primary completion 2029-06-01 · NCT06987123 · CT.gov ↗
What to watch
July 2029 (2)
Phase 4Solid TumorsRecruiting
Est. primary completion 2029-07-31 · NCT05203172 · CT.gov ↗
What to watch
Phase 4Gastric CancerNot yet recruiting
Est. primary completion 2029-07-31 · NCT07829757 · CT.gov ↗
What to watch
August 2029 (5)
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2029-08-01 · NCT06881017 · CT.gov ↗
What to watch
Phase 2ER-positive, HER2-negative Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage IIIRecruiting
Est. primary completion 2029-08-01 · NCT07631052 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2029-08-16 · NCT07431281 · CT.gov ↗
What to watch
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
Phase 3Newly Diagnosed Triple-negative Breast CancerNot yet recruiting
Est. primary completion 2029-08-31 · NCT07869628 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal CancerRecruiting
Est. primary completion 2029-09-12 · NCT06469944 · CT.gov ↗
What to watch
October 2029 (1)
Phase 1/2Colorectal CancerEnrolling by invitation
Est. primary completion 2029-10-31 · NCT07683949 · CT.gov ↗
What to watch
November 2029 (1)
Early phase / not applicableCholangiocarcinomaRecruiting
Est. primary completion 2029-11-01 · NCT06434493 · CT.gov ↗
What to watch
December 2029 (8)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-01 · NCT07222215 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal Cancinoma (NPC), Nasopharangeal CancerNot yet recruiting
Est. primary completion 2029-12-01 · NCT07238569 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2029-12-01 · NCT07365592 · CT.gov ↗
What to watch
Phase 2Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma …Active not recruiting
Est. primary completion 2029-12-31 · NCT04166318 · CT.gov ↗
What to watch
Phase 2Breast Neoplasms, Breast CancerRecruiting
Est. primary completion 2029-12-31 · NCT06797635 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2029-12-31 · NCT07283367 · CT.gov ↗
What to watch
Phase 2Rectal Neoplasms MalignantNot yet recruiting
Est. primary completion 2029-12-31 · NCT07383285 · CT.gov ↗
What to watch
Phase 3Locally Advanced Colon Cancer, pMMRNot yet recruiting
Est. primary completion 2029-12-31 · NCT07877597 · CT.gov ↗
What to watch
2030 (22)
January 2030 (3)
Phase 3Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT, Radiotherapy, Capecitabine, OxaliplatinNot yet recruiting
Est. primary completion 2030-01-01 · NCT07686796 · CT.gov ↗
What to watch
Phase 3Rectal CancerRecruiting
Est. primary completion 2030-01-30 · NCT06205485 · CT.gov ↗
What to watch
Phase 4Neoplasm Malignant, Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Carcinoma, Uterine Cervical NeoplasmsNot yet recruiting
Est. primary completion 2030-01-31 · NCT07801027 · CT.gov ↗
What to watch
February 2030 (1)
Phase 3Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance TherapyRecruiting
Est. primary completion 2030-02-20 · NCT06277050 · CT.gov ↗
What to watch
March 2030 (3)
Phase 2Gastric CancerRecruiting
Est. primary completion 2030-03 · NCT07432295 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2030-03-01 · NCT07392866 · CT.gov ↗
What to watch
Phase 2Locally Recurrent Rectal CancerRecruiting
Est. primary completion 2030-03-10 · NCT06928584 · CT.gov ↗
What to watch
May 2030 (2)
Phase 3Nasopharyngeal Carcinoma (NPC)Not yet recruiting
Est. primary completion 2030-05-01 · NCT06900218 · CT.gov ↗
What to watch
Early phase / not applicableLocally Advanced Rectal CancerNot yet recruiting
Est. primary completion 2030-05-15 · NCT07854964 · CT.gov ↗
What to watch
June 2030 (2)
Phase 3Breast Cancer, TNBCNot yet recruiting
Est. primary completion 2030-06-16 · NCT07021261 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2030-06-30 · NCT07309419 · CT.gov ↗
What to watch
July 2030 (2)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2030-07 · NCT07281768 · CT.gov ↗
What to watch
Phase 2/3Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal AdenocarcinomaActive not recruiting
Est. primary completion 2030-07-01 · NCT05610163 · CT.gov ↗
What to watch
August 2030 (2)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-08 · NCT02491697 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2030-08 · NCT07805551 · CT.gov ↗
What to watch
September 2030 (2)
Phase 2/3Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2030-09-01 · NCT06841679 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal CarcinomaRecruiting
Est. primary completion 2030-09-04 · NCT07791758 · CT.gov ↗
What to watch
October 2030 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-10-15 · NCT06525766 · CT.gov ↗
What to watch
Phase 3Pancreatic CancerRecruiting
Est. primary completion 2030-10-21 · NCT06958328 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Rectal CancerNot yet recruiting
Est. primary completion 2030-11 · NCT07580339 · CT.gov ↗
What to watch
December 2030 (2)
Phase 3Nasopharyngeal Carcinoma (NPC)Recruiting
Est. primary completion 2030-12-31 · NCT07590024 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Cancinoma (NPC)Not yet recruiting
Est. primary completion 2030-12-31 · NCT07904819 · CT.gov ↗
What to watch
2031 (16)
February 2031 (1)
Phase 2Nasopharangeal CancerRecruiting
Est. primary completion 2031-02-10 · NCT07392320 · CT.gov ↗
What to watch
June 2031 (2)
Phase 2Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer …Recruiting
Est. primary completion 2031-06-02 · NCT07340541 · CT.gov ↗
What to watch
Phase 1/2Triple Negative Breast Cancer, Residual DiseaseRecruiting
Est. primary completion 2031-06-26 · NCT06134375 · CT.gov ↗
What to watch
July 2031 (1)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2031-07-06 · NCT04383275 · CT.gov ↗
What to watch
August 2031 (1)
Phase 2Malignant Neoplasms of Digestive OrgansRecruiting
Est. primary completion 2031-08-06 · NCT05934331 · CT.gov ↗
What to watch
September 2031 (3)
Phase 3Breast NeoplasmsRecruiting
Est. primary completion 2031-09 · NCT06313463 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal Cancinoma (NPC)Recruiting
Est. primary completion 2031-09 · NCT07154069 · CT.gov ↗
What to watch
Phase 2AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma …Active not recruiting
Est. primary completion 2031-09-15 · NCT04929028 · CT.gov ↗
What to watch
October 2031 (1)
Phase 3Gastroenteropancreatic Neuroendocrine TumorsNot yet recruiting
Est. primary completion 2031-10-11 · NCT07910760 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Bladder CancerRecruiting
Est. primary completion 2031-11-17 · NCT07829783 · CT.gov ↗
What to watch
December 2031 (6)
Phase 2Nasopharyngeal Cancinoma (NPC), Nasopharyngeal CancerNot yet recruiting
Est. primary completion 2031-12 · NCT07524413 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal Cancinoma (NPC)Active not recruiting
Est. primary completion 2031-12-31 · NCT07248670 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-12-31 · NCT07467330 · CT.gov ↗
What to watch
Phase 2Rectal Cancer PatientsNot yet recruiting
Est. primary completion 2031-12-31 · NCT07521605 · CT.gov ↗
What to watch
Phase 2Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2031-12-31 · NCT07554521 · CT.gov ↗
What to watch
Phase 2HER2 + Breast Cancer, Advanced Breast CancerNot yet recruiting
Est. primary completion 2031-12-31 · NCT07766772 · CT.gov ↗
What to watch
2032 (4)
May 2032 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2032-05-31 · NCT06374459 · CT.gov ↗
What to watch
June 2032 (1)
Phase 2/3Gastric CancerNot yet recruiting
Est. primary completion 2032-06-30 · NCT07332533 · CT.gov ↗
What to watch
November 2032 (1)
Phase 3Colorectal CancerActive not recruiting
Est. primary completion 2032-11-01 · NCT07340567 · CT.gov ↗
What to watch
December 2032 (1)
Phase 3Locally Advanced Rectal Cancer (LARC), MSS (Microsatellite Stable)Not yet recruiting
Est. primary completion 2032-12-31 · NCT07551479 · CT.gov ↗
What to watch
2033 (3)
March 2033 (1)
Phase 3Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast NeoplasmsRecruiting
Est. primary completion 2033-03-23 · NCT06966700 · CT.gov ↗
What to watch
April 2033 (1)
Phase 3Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2033-04-01 · NCT05314998 · CT.gov ↗
What to watch
July 2033 (1)
Phase 3Biliary Tract Cancer (BTC)Not yet recruiting
Est. primary completion 2033-07-02 · NCT07745296 · CT.gov ↗
What to watch
2034 (1)
September 2034 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2034-09 · NCT06085742 · CT.gov ↗
What to watch
2035 (1)
June 2035 (1)
Phase 3Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Neuroendocrine TumorsNot yet recruiting
Est. primary completion 2035-06 · NCT07591493 · CT.gov ↗
What to watch
2039 (1)
October 2039 (1)
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2039-10 · NCT02598349 · CT.gov ↗
What to watch
2040 (1)
June 2040 (1)
Phase 1/2Biliary Cancer, Bile Duct Cancer, Cancer of the Bile DuctRecruiting
Est. primary completion 2040-06-01 · NCT05849480 · CT.gov ↗
What to watch

See the full readout calendar ↗